Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

Celldex also receives approval from Health Canada to open clinical sites

and establishes a collaboration with the National Cancer Institute

PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.

In the ACTIVATE phase IIa study, CDX-110 treated GBM patients showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. However, preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, a
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... results for the three and six months ended June ... On July 23, 2015, the Committee for Medicinal Products ... Zalviso™ for the management of acute moderate-to-severe post-operative pain ...
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... CHESTNUT RIDGE, N.Y. , Aug. 3, 2015 /PRNewswire/ ... will host a conference call on Friday, August 7, ... of operations for the second quarter ended June 30, ... financial information available to the public in its filings ... certain other information available on its website by following ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Patient Guide: How to Prepare for Surgery 2
... The Netherlands, June 18 Amsterdam,Molecular Therapeutics (Euronext: ... gene,therapy, announced today new data showing that a ... significant long-term health benefits.,Long-term follow-up data from two ... significant and clinically important,reduction in acute pancreatitis in ...
... Improvements in Memory and Attention , , SANTA CLARA, Calif., ... gathered at the Sixth Annual Boomer Venture Summit at Santa ... younger - their brains will actually operate like brains, and look ... of Posit Science, the leading provider of brain fitness ...
Cached Medicine Technology:Glybera(TM) Shows Long-Term Health Benefits 2Glybera(TM) Shows Long-Term Health Benefits 3Brain Fitness Makes Boomers Age Younger 2
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... patients whose cancer has come back: Retreatment may be a viable option. Surviving ... read it now. , According to surgeons at the University of New ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and other long-term care facilities, today announced details of the Advanced level of ... and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is ...
(Date:8/4/2015)... ... 04, 2015 , ... A new report by The 2112 ... will grow at least 6 percent in 2015, as solution providers expand sales, ... their OEM/vendor partners. , The 2112 Group’s 2015 Midyear Channel Performance Report ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3
... developing clothing, which they say will be able to monitor ... sensors designed to monitor body fluids such as blood and ... use the clothes to check on groups such as recovering ... ,As of now, the Biotex programme, which is ...
... of psychologists from Durham University and two Polish institutions ... their fathers are more likely to select partners ... negative or less positive relationships were not attracted to ... ,Due to be published in the July issue of ...
... total economic shutdown as some 2 million public servants ... 'It's going to be a total shutdown tomorrow in public ... involving marches in major cities and pickets outside government buildings,' ... Trade Unions (COSATU) labor federation had warned Tuesday. ...
... (CNBG) led by Madam Wang Lifeng, President and CEO ... Union Minister for Health & Family Welfare , Dr. ... CNBG is Government owned, the largest vaccine manufacturer and ... discussed the supply live of JE vaccine in order ...
... than leave you short-tempered: it can also stress your ... death, according to a study released Wednesday . ... sleep loss have been well-documented, ranging from lowered concentration ... by researchers at the University of Pennsylvania School of ...
... both houses of the Legislature are on the brink of ... the Assembly's bill is Manhattan Assemblyman Richard Gottfried , who ... serious medical conditions who could have a better quality and ... a person would have to have a debilitating or life-threatening ...
Cached Medicine News:Health News:Scientists Developing 'intelligent Clothes' to Monitor Wearer's Health 2Health News:Women Choose Their Men With Their Fathers Resemblance 2Health News:South Africa Facing Major Economic Shutdown as Health Workers are Sacked En Masse 2Health News:Chinese Delegation Meets Health Minister Regarding Japanese Encephalitis Vaccine Supply 2Health News:Insufficient Sleep Increases Risk of Cardiovascular Disease: Study 2Health News:Medical Marijuana to Be Legalized 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: